HKD5.30
2.51% yesterday
Hong Kong, Jun 27, 10:09 am CET
ISIN
KYG8167W1380
Symbol
1177
Sector
Industry

Sino Biopharmaceutical Stock price

HKD5.30
+1.05 24.71% 1M
+2.07 64.09% 6M
+2.10 65.63% YTD
+2.60 96.30% 1Y
+0.51 10.65% 3Y
-4.45 45.62% 5Y
+2.73 106.56% 10Y
+5.02 1,820.29% 20Y
Hong Kong, Closing price Fri, Jun 27 2025
+0.13 2.51%
ISIN
KYG8167W1380
Symbol
1177
Sector
Industry

Key metrics

Basic
Market capitalization
HKD92.5b
Enterprise Value
HKD87.1b
Net debt
HKD-5.3b
Cash
HKD16.0b
Shares outstanding
17.9b
Valuation (TTM | estimate)
P/E
25.24 | 28.44
P/S
2.93 | 2.58
EV/Sales
2.76 | 2.43
EV/FCF
-
P/B
2.72
Dividends
DPS
HKD0.06
Yield 1Y | 5Y
1.13% | 1.24%
Growth 1Y | 5Y
-25.00% | 2.43%
Payout 1Y | 3Y
46.15% | 22.02%
Increased
0 Years
Financials (TTM | estimate)
Revenue
HKD31.6b | HKD35.8b
EBITDA
- | HKD9.1b
EBIT
HKD6.0b
Net Income
HKD3.8b | HKD3.3b
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
14.52% | 13.46%
EBITDA
- | 12.97%
EBIT
-6.48%
Net Income
50.08% | -12.79%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
81.51%
EBITDA
- | 25.47%
EBIT
18.92%
Net
12.12% | 9.32%
Free Cash Flow
-
Financial Health
Equity Ratio
48.86%
Return on Equity
10.95%
ROCE
11.91%
ROIC
12.73%
Debt/Equity
0.30
More
EPS
HKD0.21
FCF per Share
Short interest
-
Employees
24.38k
Rev per Employee
HKD1.30m
Show more

Is Sino Biopharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Sino Biopharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

27 Analysts have issued a Sino Biopharmaceutical forecast:

25x Buy
93%
2x Hold
7%

Analyst Opinions

27 Analysts have issued a Sino Biopharmaceutical forecast:

Buy
93%
Hold
7%

Financial data from Sino Biopharmaceutical

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
31,592 31,592
15% 15%
100%
- Direct Costs 5,840 5,840
23% 23%
18%
25,752 25,752
13% 13%
82%
- Selling and Administrative Expenses 13,308 13,308
12% 12%
42%
- Research and Development Expense 5,570 5,570
16% 16%
18%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 5,976 5,976
6% 6%
19%
Net Profit 3,830 3,830
50% 50%
12%

In millions HKD.

Don't miss a Thing! We will send you all news about Sino Biopharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Sino Biopharmaceutical Ltd. is an investment holding company, which engages in the manufacture and sale of pharmaceutical products. It operates through the following business segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The Modernised Chinese Medicines and Chemical Medicines segment comprises the manufacturing, selling, and distribution of modernized Chinese medicine products and western medicine products. The Investment segment offers long term investments. The Other segment includes a research and development sector, which provides services to third-parties; and related healthcare and hospital business. It also develops medicines for treating tumors, analgesia, diabetes, and respiratory system diseases. The company was founded by Ping Tse on February 2, 2000 and is headquartered in Hong Kong.

Head office Cayman Islands
CEO S Tse
Employees 24,379
Founded 2000
Website www.sinobiopharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today